Suchergebnisse - "Podzamczer, Daniel"

PubPharm (31)

1

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von González-Cordón, A. | Assoumou, L. | Moyle, G. | +117

2

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

enthalten in: Journal of neurovirology | 2018

von Imaz, A. | Niubó, J. | Amara, A. | +7

3

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD) : 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Squires, K. | Sax, P. | +113

CommentIn: Lancet HIV. 2018 May;5(5):e200-e201. - PMID 29592841

4

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients : A Randomized, Multinational, Multicenter Trial

enthalten in: PloS one | 2016

von Cooper, D. | Cordery, D. | Zajdenverg, R. | +87

5

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

enthalten in: Antiviral therapy | 2016

von Tiraboschi, J. | Knobel, H. | Imaz, A. | +9

6

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE) : a randomised, open-label, non-inferiority trial

enthalten in: The Lancet. Infectious diseases | 2015

von Arribas, J. | Girard, P. | Landman, R. | +118

CommentIn: Lancet Infect Dis. 2015 Jul;15(7):748-9. - PMID 26062879

7

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine : Final 48-Week Results (The Advanz-3 Trial)

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2015

von Miro, J. | Manzardo, C. | Ferrer, E. | +45

8

Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression

enthalten in: The Journal of antimicrobial chemotherapy | 2015

von Di Yacovo, M. | Moltó, J. | Ferrer, E. | +10

9

Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

enthalten in: Antiviral therapy | 2015

von Blanco, J. | Gonzalez-Cordón, A. | Llibre, J. | +12

10

Short communication : focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

enthalten in: AIDS research and human retroviruses | 2014

von Imaz, A. | Cayuela, N. | Niubó, J. | +4